SPOTLIGHT -
EP. 1: Current Frontline Management of Small Cell Lung Cancer
EP. 2: Small Cell Lung Cancer: Interpreting Data From IMpower133
EP. 3: Results From the CASPIAN Trial in SCLC
EP. 4: Frontline I-O Strategies in SCLC: Practical Implications
EP. 5: I-O Strategies in Relapsed/Refractory SCLC
EP. 6: Small Cell Lung Cancer: Future Directions in Care
EP. 7: The Initial Approach to SCLC Treatment
EP. 8: SCLC Therapy: First-line Options Prior to Immunotherapy
EP. 9: Checkpoint Inhibitors in Second and Third-line
EP. 10: Negative I/O Trials: CheckMate331 and CheckMate 451
EP. 11: Immunotherapy Toxicity Profile
EP. 12: First-line Immunotherapy: IMPower133 Regimen
EP. 13: Frontline Therapy Approaches for Small Cell Lung Cancer
EP. 14: Immunotherapy in Relapsed-Refractory SCLC
EP. 15: The CASPIAN Trial in Extensive-Stage SCLC
EP. 16: The ADRIATIC Trial in Limited-Stage SCLC
EP. 17: Frontline and R/R Therapy and PD-L1 Targeted Therapy for SCLC
EP. 18: Emerging Therapies for Extensive Stage SCLC and CASPIAN Trial
EP. 19: Novel Agents for R/R and the Future of Extensive Stage SCLC
EP. 20: I/O Combination Regimens & the Importance of Biomarkers
EP. 21: The CASPIAN Versus IMpower133 Regimen
EP. 22: Second- & Third-line options after Chemotherapy or I/O
EP. 23: DLL3-Targeted and Chemo-Sensitive Therapy
EP. 24: Limited-Stage SCLC Management
EP. 25: Limited-Stage SCLC Ongoing Trials
EP. 26: The Future of SCLC Management
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
